As the industry emerges from a prolonged funding slowdown, a more selective and strategically focused outlook is beginning to take shape.
In this latest article, 24/7 Biopharma brings together perspectives from industry experts to explore how the landscape is shifting. Rather than a broad upswing, experts point to momentum concentrated around clinic‑ready programmes, higher‑complexity modalities and development pathways supported by stronger data. This evolution is moving discussions away from speculative innovation and toward the practical factors that now define success: manufacturability, reliable timelines, and the ability to scale with confidence.
Christian Dowdeswell, Managing Director at Arcinova, shares candid insights on the cautious optimism returning to BioPharma funding—highlighting why decision‑making is moving beyond simple cost considerations and how a tailored, molecule‑specific approach can lead to stronger outcomes.
He also points to where the most meaningful growth opportunities are likely to emerge over the next 12–18 months, while addressing one of the biggest misconceptions many pharma companies still hold about working with CRDMOs.
Read the full article here to discover why a more disciplined, value‑led approach to partnership is defining the next phase of growth.
Credit:
24/7 Biopharma